<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1006245404
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Famotidine for oral suspension
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FAMOTIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40-5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 25°C Don't Freez, Protect From Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1649.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Apothecon Pharmaceuticals PVT Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Apothecon Pharmaceuticals PVT Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Navinta LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your medicine is called Famotidine for Oral Suspension, USP 40 mg/5 mL. In this leaflet, it will be called as Famotidine.</p><p>&nbsp;</p><p>Famotidine is a competitive inhibitor of histamine-2 (H<sub>2</sub>) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.</p><p>&nbsp;</p><p>Famotidine indicated in adults for the treatment of:</p><p>&bull; active duodenal ulcer (DU).</p><p>&bull; active gastric ulcer (GU).</p><p>&bull; symptomatic nonerosive gastroesophageal reflux disease (GERD).</p><p>&bull; erosive esophagitis due to GERD, diagnosed by biopsy.</p><p>&bull; treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).</p><p>&bull; reduction of the risk of duodenal ulcer recurrence.</p><p>&nbsp;</p><p>Famotidine is indicated in paediatric patients 1 year of age and older for the treatment of:</p><p>&bull; peptic ulcer disease.</p><p>&bull; GERD with or without esophagitis and ulcerations.</p><p>&nbsp;</p><p>Famotidine is indicated in paediatric patients from birth to less than 1 year of age for the treatment of:</p><p>&bull; GERD.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Famotidine if:</strong></p><p>&middot; You are allergic to Famotidine, other H2-receptor antagonists or any of the other ingredients of this medicine (listed in section 6)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>Talk to your doctor before taking Famotidine if:</strong></p><p>&middot; You suffer from kidney problems</p><p>&middot; You have been taking a high dose of Famotidine for a long time. Your doctor may monitor your blood count and liver function</p><p>&middot; Central Nervous System Adverse Reactions</p><p>Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function dosage adjustments are recommended in patients with renal impairment.</p><p>&middot; Concurrent Gastric Malignancy</p><p>In adults, symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with famotidine</p><p>&nbsp;</p><p><strong>Other medicines and Famotidine </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without prescription. This includes herbal medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Drugs Dependent on Gastric pH for Absorption</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug like dasatinib, delavirdine mesylate, cefditoren and fosamprenavir is not recommended.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Other drugs dependent on gastric pH for absorption for administration includes atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/ sofosbuvir, nilotinib, and rilpivirine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tizanidine (CYP1A2 Substrate)</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use with Famotidine for oral suspension. If concomitant use is necessary, monitor for hypertension, bradycardia or excessive drowsiness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Probenicid, used to treat gout</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Antacids, for indigestion (famotidine should be administered 1-2 hours before taking an antacid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sucralfate, used to treat and prevent the recurrence of ulcers (sucralfate should not be administered within 2 hours of taking famotidine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Calcium carbonate, when used as a medicine for high blood phosphate levels in patients on dialysis</p><p><strong>&nbsp;</strong></p><p><strong>Use in Specific population</strong></p><p><strong>Pregnancy, breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>If you are pregnant or suspect you are pregnant, you should not take Famotidine unless your doctor thinks the benefits outweigh the risks.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>If you are breast-feeding, you should either stop taking Famotidine or stop breast-feeding<strong> </strong>as it is excreted in breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Whilst taking Famotidine you may feel dizzy or have a headache. If you develop these symptoms, you should not drive or operate machinery or do activities which require you to be alert and have quick reactions.</p><p>&nbsp;</p><p><strong>Famotidine contains Sodium Benzoate</strong></p><p>This medicine contains 5.00 mg of Sodium Benzoate in each dosage unit.</p><p>Sodium Benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).</p><p>&nbsp;</p><p><strong>Famotidine contains Sodium</strong></p><p>This medicinal product contains up to 0.798 mg sodium per unit dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>How to use Famotidine </strong></p><p>&nbsp;</p><p>Always take Famotidine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><u>Preparation of Constituted Suspension </u></p><p>Prior to dispensing, constitute famotidine by slowly adding 46 ml of Purified water to the bottle. Shake vigorously for the 5 to 10 seconds immediately after adding the water. The constituted suspension contains 40 mg of famotidine per 5 ml, and should be a<em> </em>smooth, mobile, off-white, and homogeneous suspension.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the bottle of constituted suspension vigorously for 5 to 10 seconds prior to each use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take famotidine once daily before bedtime or twice daily in the morning and before bedtime.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Famotidine may be taken with or without food</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Famotidine may be given with antacids (famotidine should be administered 1-2 hours before taking an antacid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the constituted suspension at 25&deg;C (77&deg;F). Protect from freezing. Discard unused constituted suspension after 30 days.</p><p>&nbsp;</p><p><u>Dosage in adults</u></p><p>The recommended dosage and duration of famotidine in adults with normal renal function is shown in Table 1.</p><p>&nbsp;</p><p>Table 1: Recommended Dosage and Duration of Famotidine for Oral Suspension<sup>a</sup> in Adults with</p><p>Normal Renal Function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Recommended duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Active DU</p></td><td style="vertical-align:top"><p>40 mg once daily; or 20 mg twice daily<sup>b</sup></p></td><td style="vertical-align:top"><p>Up to 8 weeks<sup>c,d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Active GU</p></td><td style="vertical-align:top"><p>40 mg once daily</p></td><td style="vertical-align:top"><p>Up to 8 weeks<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic nonerosive GERD</p></td><td style="vertical-align:top"><p>20 mg twice daily</p></td><td style="vertical-align:top"><p>Up to 6 weeks<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Erosive esophagitis due to GERD, diagnosed by endoscopy</p></td><td style="vertical-align:top"><p>20 mg twice daily; or 40 mg twice daily<sup>b</sup></p></td><td style="vertical-align:top"><p>Up to 12 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Pathological hypersecretory conditions</p></td><td style="vertical-align:top"><p>Starting dosage: 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours</p></td><td style="vertical-align:top"><p>As clinically indicated</p></td></tr><tr><td style="vertical-align:top"><p>Reduction of the risk of DU recurrence</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>1 year<sup>c,d</sup> or as clinically indicated</p></td></tr></tbody></table><p>a&nbsp;&nbsp; After preparation, the concentration of famotidine is 8 mg/mL</p><p>b&nbsp;&nbsp; Both dosages demonstrated effectiveness in clinical trials</p><p>c&nbsp;&nbsp; In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4</p><p>&nbsp;&nbsp;&nbsp; weeks, consider an additional 2 to 4 weeks of treatment</p><p>d&nbsp;&nbsp; Longer treatment durations have not been studied in clinical trials</p><p>&nbsp;</p><p><u>Dosage in Paediatric</u></p><p>The recommended dosage and duration of famotidine in paediatric patients with normal renal function is shown in Table 2.</p><p>&nbsp;</p><p>Table 2: Recommended Dosage and Duration of Famotidine for Oral Suspension<sup>a</sup> in Paediatric Patients with Normal Renal Function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Age</strong></p><p><strong>Range</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dosage<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Peptic Ulcer</strong></p><p><strong>Disease</strong></p></td><td style="vertical-align:top"><p>1 year to less than</p><p>17 years</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg once daily; or 0.25 mg/kg twice daily.</p><p>&nbsp;</p><p>May increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily</p><p>&nbsp;</p><p>Maximum of 40 mg per day</p></td><td style="vertical-align:top"><p>8 weeks<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>GERD</strong></p></td><td style="vertical-align:top"><p>Birth to less than</p><p>3 months</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg once daily.</p><p>May increase to 1 mg/kg once daily<sup>b</sup></p></td><td rowspan="2" style="vertical-align:top"><p>Up to 8 weeks<sup>b,c,d</sup></p></td></tr><tr><td style="vertical-align:top"><p>3 months to less than</p><p>1 year</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg twice daily.</p><p>May increase to 1 mg/kg twice daily<sup>c</sup></p><p>&nbsp;</p><p>Maximum of 40 mg per day</p></td></tr><tr><td style="vertical-align:top"><p><strong>GERD with or</strong></p><p><strong>without</strong></p><p><strong>esophagitis and</strong></p><p><strong>ulcerations</strong></p></td><td style="vertical-align:top"><p>1 year to less than</p><p>17 years</p></td><td style="vertical-align:top"><p>0.5 mg/kg twice daily</p><p>Maximum of 40 mg twice daily</p></td><td style="vertical-align:top"><p>6 to 12 weeks<sup>b</sup></p></td></tr></tbody></table><p>a &nbsp;&nbsp;After preparation, the concentration of famotidine is 8 mg/mL</p><p>b &nbsp;&nbsp;Treatment duration based on adult recommendations (see Table 1). Individualize the dose and</p><p>&nbsp;&nbsp;&nbsp;&nbsp; duration based upon clinical response and/or pH determinations (gastric or esophageal) and</p><p>&nbsp;&nbsp;&nbsp;&nbsp; endoscopy.</p><p>c &nbsp;&nbsp;Use conservative measures (e.g., thickened feedings) concurrently</p><p>d &nbsp;&nbsp;After 4 weeks of treatment re-evaluate the patient. Consider an additional 4 weeks of treatment if</p><p>&nbsp;&nbsp;&nbsp;&nbsp; treatment benefit outweighs potential risks.</p><p>&nbsp;</p><p><u>Dosage in Adults with Renal Impairment</u></p><p>Recommended dosage adjustments for adults with moderate to severe renal impairment (creatinine</p><p>clearance less than 60 mL/min) by indication are shown in Table 3. Use the lowest effective dosage</p><p>A safe and effective dosage has not been established in pediatric patients with renal impairment.</p><p>&nbsp;</p><p>Table 3: Recommended Maximum Dosage of Famotidine for Oral Suspension in Adults with</p><p>Moderate and Severe Renal Impairment</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Indication</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp; Recommended Maximum dosages</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine clearance 30 to 60 mL/minute</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance less than 30 ML/minute</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Active DU</strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Active GU</strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Symptomatic nonerosive GERD</strong></p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Erosive esophagitis due to GERD, diagnosed by endoscopy<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day<sup>b</sup></p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>40 mg once daily<sup>b</sup></p></td><td style="vertical-align:top"><p>20 mg once daily<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pathological hypersecretory conditions</strong></p></td><td colspan="2" style="vertical-align:top"><p>Avoid use<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Reduction of the risk of DU recurrence</strong></p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td><td style="vertical-align:top"><p>10 mg every other day</p></td></tr></tbody></table><p>a Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg</p><p>&nbsp;&nbsp; twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials</p><p>b The dosage required to treat pathological hypersecretory conditions may exceed the maximum dosage evaluated</p><p>&nbsp;&nbsp; in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients</p><p>&nbsp;&nbsp; treated with famotidine for pathological hypersecretory conditions is unknown.</p><p>&nbsp;</p><p><u>If you use more Famotidine than you should</u></p><p>If you accidentally take more suspension, contact your doctor or nearest hospital emergency department immediately<strong> </strong>for advice. Remember to take this leaflet.</p><p>&nbsp;</p><p><u>If you forget to take Famotidine</u></p><p>If you forget to take your dose of Famotidine, unless it is almost time for your next dose, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><u>If you stop taking Famotidine</u></p><p>If you have had stomach or intestinal ulcers for a long time you should not stop taking Famotidine if you feel better, without asking for advice from your doctor first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop taking Famotidine and contact your doctor or go to your nearest hospital emergency department immediately if you notice any of the following:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a serious allergic reactions including rash, itching or hives, shortness of breath, wheezing or trouble breathing, or swelling of the face, hands, feet, mouth, throat or eyes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin or whites of the eyes, dark urine, pale stools, persistent lack of appetite or abdominal pain which may be signs of serious liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe blistering rash with bleeding in the lips, eyes, mouth, nose and genitals or severe skin reactions which starts with painful red areas, then large blisters and ends with peeling of the surface layers of the skin. You may have Stevens-Johnson syndrome or condition known as Toxic Epidermal Necrolysis (TEN), which may be life-threatening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a burning sensation in the chest, shortness of breath and a persistent cough (these may be signs you have a lung infection (pneumonia) which may be severe). You may also get tired, have blue lips or fingertips (cyanosis) or lose weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits or seizures where you may lose consciousness, cry out or have jerky movements, feel a warning (aura) beforehand and afterwards may be confused, tired or have a severe headache. If you have kidney problems you are more at risk of seizures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to the electrical activity of the heart seen on an EEG. You may feel lightheaded. Patients given this type of medicine by injection, have experienced some changes in heart rhythm or an irregular heartbeat.</p><p>&nbsp;</p><p><strong>Stop taking Famotidine and contact your doctor as soon as possible if you notice any of the following:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the number of infections, you may get such as fever, severe chills, sore throat or mouth ulcers (these may be the signs that you have a low number of white blood cells in the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low numbers of other blood cells, causing tiredness, shortness of breath, coldness in your hands and feet and pale skin (low number of red blood cells), unusual bruising or bleeding more easily than normal, difficulty in healing after a cut (low number of platelets)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression, confusion, feeling disorientated, anxious or agitated, or seeing, hearing or feeling things that are not real (hallucinations)</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unusually tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling bloated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin or rash</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in liver enzymes in the blood, seen in a blood test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged breasts in men. However it is not certain this effect is caused by famotidine.</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty getting or maintaining an erection or a reduction in your sex drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness in the fingers and toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in blood liver enzymes seen in a blood test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain or muscle cramps</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p><strong>&nbsp;</strong></p><p>Store famotidine dry powder and constituted suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F)</p><p>Protect from freezing. Discard unused constituted suspension after 30 days.</p><p>Dispense in a USP tight, light-resistant container.</p><p>&nbsp;</p><p>Prior to dispensing, constitute famotidine for oral suspension.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Famotidine For Oral Suspension contains 40mg of Famotidine per 5 ml.</p><p>&nbsp;</p><p><strong>The other ingredients are</strong></p><p>Confectioners sugar</p><p>Microcrystalline Cellulose/Carboxy methyl Cellulose sodium</p><p>Xanthan gum</p><p>Sodium benzoate</p><p>Methyl Paraben sodium</p><p>Citric acid anhydrous</p><p>Purified water</p><p>Mint flavour</p><p>Cherry flavour</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Description: white to off-white powder. When constituted as directed, famotidine suspension is a smooth, mobile, off- white, homogeneous suspension with a cherry-mint flavor, containing 40 mg of famotidine per 5 mL.

Pack size: Bottle with the leaflet fixed to the bottle cap.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Navinta LLC</p><p>Ewing, NJ-08618, USA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Apothecon Pharmaceuticals Private Limited</p><p>Address: Plot No. 1134, 1135, 1136, 1137,</p><p>1138-A&amp;B, 1143-B, 1144-A&amp;B, Padra Jambusar Highway,</p><p>Dabhasa, Padra, Vadodara, Gujarat- IN 391440 India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in September 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم دوائك فاموتيدين المعلق الفموي 40 ملغ/5 مل (وفق دستور الأدوية الأمريكي)، ويشار إليه في هذه النشرة باسم فاموتيدين.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">فاموتيدين مثبِّطٌ تنافسي لمستقبِلات الهِستامين 2 (H<sub>2</sub>). وأول عملٍ دوائي مهم سريريًّا لفاموتيدين هو تثبيط الإفراز المَعِدِي؛ فهو يثبِّط كلًّا من مقدار الإفراز المَعِدي وتركيزه الحمضي، وأما التغيرات في إفراز الببسين فتتناسب ومقدار ناتج الإفراز.</p><p>&nbsp;</p><p dir="RTL">يوصَف فاموتيدين للبالغين في علاج ما يلي:</p><p dir="RTL">&bull; القرحة الاثناعشرية النشطة</p><p dir="RTL">&bull; قرحة المعدة النشطة</p><p dir="RTL">&bull; داء الارتجاع المعِدي المريئي المصاحَب بأعراض دون تآكل المريء.</p><p dir="RTL">&bull; التهاب المريء التآكلي بسبب الارتجاع المعِدي المريئي، ويشخَّص بخزعة (إجراء للحصول على عينة من النسيج).</p><p dir="RTL">&bull; حالات فرط الإفرازات المرضية (مثل متلازمة زولِنجر-إليسون، والأورام الصماوية المتعددة).</p><p dir="RTL">&bull; تقليل خطر تكرار الإصابة بقرحة الاثني عشر.</p><p>&nbsp;</p><p dir="RTL">يوصَف فاموتيدين للأطفال من سنّ سنةٍ فأكثر في علاج ما يلي:</p><p dir="RTL">&bull; داء القرحة الهضمية.</p><p dir="RTL">&bull; الارتجاع المعِدي المريئي وحده أو المصاحَب بالتهاب المريء وتقرحات.</p><p>&nbsp;</p><p dir="RTL">يوصَف فاموتيدين للأطفال من الميلاد إلى أقل من سنة في علاج ما يلي:</p><p dir="RTL">&bull; الارتجاع المعِدي المريئي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فاموتيدين فيما يلي:</strong></p><p dir="RTL">&middot; إن كانت بك حساسية من فاموتيدين أو المثبِّطات الأخرى لمستقبل الهِستامين (H2) أو غير ذلك من مكونات الدواء (المذكورة في القسم 6).</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>استشر الطبيب قبل تناول فاموتيدين فيما يلي:</strong></p><p dir="RTL">&middot; إن كانت بك علةٌ كُلويَّة.</p><p dir="RTL">&middot; إن كان لك مدة طويلة وأنت تتناول جرعة كبيرة من فاموتيدين. قد يتابع الطبيبُ تعدادَ الدم ووظائف الكبد.</p><p dir="RTL">&middot; الآثار الجانبية في الجهاز العصبي المركزي</p><p dir="RTL">من الآثار الجانبية في الجهاز العصبي المركزي تشوش الذهن، والهذيان، والهلاوس، والتَوَهان، والهياج، والتشنجات، والنعاس، وقد أبلِغَ بهذه الآثار في المرضى المسنّين والمصابين بالقصور الكُلَوي المتوسط والشديد ويخضعون للعلاج بفاموتيدين. كمية الفاموتيدين في دم المصابين بالقصور الكُلَوي أكثر منها في المرضى ذوي وظائف الكُلى الطبيعية؛ ولذا يوصى بتعديل الجرعة للمصابين بالقصور الكُلَوي.</p><p dir="RTL">&middot; الإصابة المتزامنة بورم خبيث في المعدة</p><p dir="RTL">استجابة أعراض البالغين للعلاج بفاموتيدين لا يمنع وجود ورم خبيث في المعدة، فينبغي مراعاة تقييم الورم المعِدي الخبيث في المرضى البالغين الذين يستجيبون استجابةً دون المثلى أو ينتكسون مبكرًا بعد إتمام العلاج بفاموتيدين.</p><p>&nbsp;</p><p dir="RTL"><strong>فاموتيدين مع غيره من الأدوية </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني إن كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، حتى الأدوية التي تُصرَف دون وصفة طبية، والأدوية العشبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعتمدة في امتصاصها على درجة حموضة المعدة</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; يوصى بعدم تناول فاموتيدين معها؛ فقد يقلل فاموتيدين امتصاصَ الأدوية الأخرى بسبب تأثيره في تقليل حامضية المعدة، فيفقد الدواء المصاحب فعاليته كأدوية دَساتينيب، ودِلافِردين مِسيلات، وسِفدِتورين، وفوسَمبرينافير.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; ومن الأدوية الأخرى التي تعتمد في امتصاصها على درجة حموضة المعدة أتازَنافير، وإرلوتِنيب، وكيتوكونازول، وإتراكونازول، ولِديبَسْفير أو سوفُسْبَفير، ونيلوتِنيب، ورِلْبِفِرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تِزانيدين (ركيزة إنزيم CYP1A2)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; يعَدّ فاموتيدين مثبطًا ضعيفًا لإنزيم CYP1A2، وقد يؤدي إلى زيادة كبيرة في تركيز تِزانيدين في الدم، وهو ركيزة إنزيم CYP1A2، مع أن هذا الأمر ليس فيه دراسة سريرية. فيُمتنع عن تناول فاموتيدين المعلق الفموي بالتزامن مع هذا الدواء، وإن كان تناوله ضروريًّا؛ فيُراقَب ارتفاع ضغط الدم أو بطء القلب أو فرط الشعور بالنُعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بروبِنيسيد، لعلاج النقرس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة لعلاج عسر الهضم (ينبغي إعطاء فاموتيدين قبل تناول أحد مضادات الحموضة بساعة إلى ساعتين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سَكرَلْفات، لعلاج التقرحات والوقاية من تكرار الإصابة بها (ولا يصح تناوله في ساعتين من تناول فاموتيدين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كربونات الكالسيوم يستخدَم دواءً لعلاج ارتفاع معدل الفُسفات في دم المرضى الخاضعين للغسل الكلوي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام في فئات بعينها</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إن كنتِ حاملًا أو مرضعًا، أو تظنين أنكِ حامل أو تنوين الإنجاب، فاستشيري الطبيب أو الصيدلاني قبل تناول هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إن كنتِ حاملًا أو تظنين أنكِ حامل؛ فلا يصح تناول فاموتيدين إلا إن رأى الطبيب أن فوائده أرجح من مخاطره.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">إن كنتِ ترضعين رضاعةً طبيعية؛ فينبغي الامتناع إما عن تناول فاموتيدين أو عن الرضاعة الطبيعية لأن الدواء يفرَز في حليب الثدي.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بدوار أو تصاب بصداع في أثناء تناول فاموتيدين، فإن ظهرت عليك هذه الأعراض، فاترك القيادة وتشغيل الآلات والأعمال التي تتطلب اليقظة وسرعة الاستجابة.</p><p>&nbsp;</p><p dir="RTL"><strong>احتواء فاموتيدين على بنزوات الصوديوم</strong></p><p dir="RTL">يحتوي الدواء على 5 ملغ من بنزوات الصوديوم في كل جرعة،</p><p dir="RTL">وقد يزيد بنزوات الصوديوم حدوث اليرقان (اصفرار الجلد والعينين) في حديثي الولادة (حتى سنّ 4 أسابيع).</p><p>&nbsp;</p><p dir="RTL"><strong>احتواء فاموتيدين على الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على قدر من الصوديوم يصل إلى 0,798 ملغ لكل جرعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول فاموتيدين إلا كما أرشدك الطبيب، وإن شككت فعليك استشارة الطبيب أو الصيدلاني.</p><p>&nbsp;</p><p dir="RTL"><u>تحضير المعلق </u></p><p dir="RTL">قبل صرف الدواء، يحضَّر فاموتيدين بإضافة 46 مل من الماء المنقَّى إلى القارورة ببطء، ويرَجّ بقوة من 5 إلى 10 ثوانٍ فور إضافة الماء. يحتوي المعلق المحضَّر على 40 ملغ من فاموتيدين لكل 5 مل، وينبغي أن يكون المعلق زَلِقًا ومتحركًا وأبيضَ مصفرًّا ومتجانسًا.</p><p>&nbsp;</p><p dir="RTL"><u>طريقة إعطاء الدواء</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترَجّ قارورة المعلق المحضَّر بقوة من 5 إلى 10 ثوانٍ قبل كل استخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوَلْ فاموتيدين مرةً يوميًّا قبل النوم أو مرتين إحداهما صباحًا والأخرى قبل النوم.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>يؤخَذ فاموتيدين مع الطعام أو من دونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجوز أن يعطَى فاموتيدين مع مضادات الحموضة (ويُعطى قبل تناول أحدها بساعة إلى ساعتين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزَّن المعلق المحضَّر في درجة حرارة 25 درجة مئوية (77 درجة فهرنهايت). ويُحفظ من التجميد، ويُتخلَّص منه إن مرَّ عليه 30 يومًا من غير استعمال.</p><p>&nbsp;</p><p dir="RTL"><u>الجرعة للبالغين</u></p><p dir="RTL">يُرجَى الاطلاع على الجدول 1 لمعرفة جرعة فاموتيدين ومدة العلاج الموصى بهما للبالغين ذوي وظائف كُلى طبيعية.</p><p>&nbsp;</p><p dir="RTL">الجدول 1: جرعة فاموتيدين المعلق الفموي<sup>أ</sup> ومدة العلاج الموصى بهما للبالغين ذوي</p><p dir="RTL">وظائف كُلى طبيعية.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>دواعي الاستعمال</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الموصى بها</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدة العلاج الموصى بها</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">القرحة الاثناعشرية النشطة</p></td><td style="vertical-align:top"><p dir="RTL">40 ملغ مرةً يوميًّا، أو 20 ملغ مرتين يوميًّا<sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">حتى 8 أسابيع<sup>ج، د</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قرحة المعدة النشطة</p></td><td style="vertical-align:top"><p dir="RTL">40 ملغ مرةً يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">حتى 8 أسابيع<sup>د</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;الارتجاع المعِدي المريئي المصاحَب بأعراض دون تآكل المريء</p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرتين يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">حتى 6 أسابيع<sup>د</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب المريء التآكلي بسبب الارتجاع المعِدي المريئي، يشخَّص بالمنظار الداخلي</p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ أو 40 ملغ مرتين يوميًّا<sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">حتى 12 أسبوعًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حالات فرط الإفرازات المرضية</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة الأولية: 20 ملغ كل 6 ساعات، وتعدَّل الجرعة بحسب حاجات كل مريض على حدة، على ألا تتجاوز الجرعة 160 ملغ كل 6 ساعات</p></td><td style="vertical-align:top"><p dir="RTL">بحسب ما يوصَف سريريًّا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تقليل خطر تكرار الإصابة بقرحة الاثني عشر</p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">عام واحد<sup>ج،د</sup>، أو بحسب ما يوصَف سريريًّا</p></td></tr></tbody></table><p dir="RTL">أ&nbsp;&nbsp; يكون تركيز فاموتيدين 8 ملغ/مل بعد التحضير</p><p dir="RTL">ب&nbsp;&nbsp; كلتا الجرعتين أثبتت فعالية في التجارب السريرية</p><p dir="RTL">ج&nbsp;&nbsp; تم شفاء أغلب المرضى في التجارب السريرية في 4 أسابيع. وأما المرضى الذين لم يتعافَوا بعد 4</p><p dir="RTL">&nbsp;&nbsp;&nbsp; أسابيع، فيراعى زيادة مدة العلاج أسبوعين إلى 4 أسابيع</p><p dir="RTL">د&nbsp;&nbsp; لم تدرَسْ فترات علاجٍ أطول في التجارب السريرية</p><p>&nbsp;</p><p dir="RTL"><u>الجرعة للأطفال</u></p><p dir="RTL">في الجدول 2 جرعة فاموتيدين ومدة العلاج الموصى بهما للمرضى الأطفال ذوي وظائف كُلى طبيعية.</p><p>&nbsp;</p><p dir="RTL">الجدول 2: جرعة فاموتيدين المعلق الفموي<sup>أ</sup> ومدة العلاج الموصى بهما للمرضى الأطفال ذوي وظائف كُلى طبيعية.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>دواعي الاستعمال</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدى سنّ الطفل</strong></p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة الموصى بها<sup>أ</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدة العلاج</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>داء القرحة الهضمية</strong></p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">من عام إلى أقل من 17 عامًا</p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة الأولية 0,5 ملغ/كغ مرةً يوميًّا، أو 0,25 ملغ/كغ مرتين يوميًّا،</p><p dir="LTR">&nbsp;</p><p dir="RTL">وقد تزيد إلى 1 ملغ/كغ مرةً يوميًّا عند النوم، أو 0,5 ملغ/كغ مرتين يوميًّا.</p><p dir="LTR">&nbsp;</p><p dir="RTL">الجرعة القصوى 40 ملغ يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">8 أسابيع<sup>ب</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL"><strong>الارتجاع المعِدي المريئي</strong></p></td><td style="vertical-align:top"><p dir="RTL">من الميلاد إلى أقل من</p><p dir="RTL">3 أشهر</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة الأولية 0,5 ملغ/كغ مرةً يوميًّا،</p><p dir="RTL">وقد تزيد إلى 1 ملغ/كغ مرةً يوميًّا<sup>ب</sup></p></td><td rowspan="2" style="vertical-align:top"><p dir="RTL">حتى 8 أسابيع<sup>ب،ج، د</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 3 أشهر إلى أقل من</p><p dir="RTL">عام</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة الأولية 0,5 ملغ/كغ مرتين يوميًّا،</p><p dir="RTL">وقد تزيد إلى 1 ملغ/كغ مرتين يوميًّا<sup>ج</sup></p><p dir="LTR">&nbsp;</p><p dir="RTL">الجرعة القصوى 40 ملغ يوميًّا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الارتجاع المعِدي المريئي وحده أو المصاحَب بالتهاب المريء وتقرحات</strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">من عام إلى أقل من</p><p dir="RTL">17 عامًا</p></td><td style="vertical-align:top"><p dir="RTL">0,5 ملغ/كغ مرتين يوميًّا</p><p dir="RTL">الجرعة القصوى 40 ملغ مرتين يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">من 6 أسابيع حتى 12 أسبوعًا<sup>ب</sup></p></td></tr></tbody></table><p dir="RTL">أ&nbsp;&nbsp; يكون تركيز فاموتيدين 8 ملغ/مل بعد التحضير</p><p dir="RTL">ب&nbsp;&nbsp; مدة العلاج بحسب التوصيات للبالغين (انظر الجدول 1). تحدَّد الجرعة ومدة العلاج بحسب كل مريض على حدة بناءً على الاستجابة السريرية، أو تحديد درجة الحموضة في المعدة والمريء، أو كليهما، فضلًا عن التنظير الداخلي.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">ج&nbsp;&nbsp; تُتّخَذ التدابير التحفظية (كالرضعات الثخينة) مع العلاج</p><p dir="RTL">د&nbsp;&nbsp; بعد 4 أسابيع من العلاج يعاد تقييم حالة المريض. تُراعى زيادة مدة العلاج 4 أسابيع إن</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; كان نفع العلاج يفوق مخاطره المحتملة.</p><p>&nbsp;</p><p dir="RTL"><u>الجرعة للبالغين المصابين بالقصور الكُلَوي</u></p><p dir="RTL">في الجدول 3 تعديل الجرعات الموصى به للبالغين المصابين بقصور كُلوي متوسط إلى شديد (حيث تصفية الكرياتينين أقل من 60 مل/دقيقة) وفق دواعي الاستعمال.</p><p dir="RTL">&nbsp;تستخدَم أقل الجرعات فعالية.</p><p dir="RTL">لم تقرَّر جرعة آمنة وفعالة للمرضى الأطفال المصابين بالقصور الكُلَوي.</p><p>&nbsp;</p><p dir="RTL">الجدول 3: الجرعة القصوى الموصى بها من فاموتيدين المعلق الفموي للبالغين المصابين</p><p dir="RTL">بالقصور الكُلَوي المتوسط والشديد.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL"><strong>دواعي الاستعمال</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>&nbsp; الجرعات القصوى الموصى بها</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>تصفية الكرياتينين من 30 إلى 60 مل/الدقيقة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>تصفية الكرياتينين أقل من 30 مل/الدقيقة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>القرحة الاثناعشرية النشطة</strong></p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا، أو 40 ملغ كل يومين</p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ مرةً يوميًّا، أو 20 ملغ كل يومين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>قرحة المعدة النشطة</strong></p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا، أو 40 ملغ كل يومين</p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ مرةً يوميًّا، أو 20 ملغ كل يومين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;الارتجاع المعِدي المريئي المصاحَب بأعراض دون تآكل المريء</strong></p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا</p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ مرةً يوميًّا، أو 20 ملغ كل يومين</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL"><strong>التهاب المريء التآكلي بسبب الارتجاع المعِدي المريئي، يشخَّص بالمنظار الداخلي<sup>أ</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا، أو 40 ملغ كل يومين<sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ مرةً يوميًّا، أو 20 ملغ كل يومين<sup>ب</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">40 ملغ مرةً يوميًّا<sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">20 ملغ مرةً يوميًّا<sup>ب</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>حالات فرط الإفرازات المرضية</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">يمتنَع عن الاستخدام<sup>ب</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>تقليل خطر تكرار الإصابة بقرحة الاثني عشر</strong></p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ مرةً يوميًّا، أو 20 ملغ كل يومين</p></td><td style="vertical-align:top"><p dir="RTL">10 ملغ كل يومين</p></td></tr></tbody></table><p dir="RTL">أ تعديل الجرعات لمرضى القصور الكُلوي لكلا نظامي الجرعة (20 ملغ مرتين يوميًّا و40 ملغ مرتين يوميًّا) أظهر فعالية علاج التهاب المريء التآكلي في التجارب السريرية</p><p dir="RTL">&nbsp;&nbsp;</p><p dir="RTL">ب الجرعة اللازمة لعلاج حالات فرط الإفرازات المرضية قد تتجاوز الجرعة القصوى المقدَّرة للمصابين بقصور وظائف الكُلى.</p><p dir="RTL">&nbsp;&nbsp;&nbsp; يُجهَل خطر زيادة الآثار الجانبية الضارة بمرضى القصور الكُلَوي الذين يتناولون فاموتيدين لعلاج حالات فرط الإفرازات المرضية.</p><p dir="RTL">&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><u>تجاوز الجرعة الموصوفة من فاموتيدين</u></p><p dir="RTL">إن تجاوزتَ جرعة المعلق عَرَضًا، فاستشر الطبيب أو الصيدلاني أو اذهبْ إلى قسم الطوارئ بأقرب مستشفًى فورًا، ولا تنسَ أخذ هذه النشرة معك.</p><p>&nbsp;</p><p dir="RTL"><u>نسيان تناول فاموتيدين</u></p><p dir="RTL">إن نسيتَ تناول جرعة فاموتيدين، فتناولها إذا ما ذكرتَها، إلا إن اقترب موعد الجرعة التالية، ولا تضاعف الجرعة لتعويض الجرعة المنسيَّة.</p><p>&nbsp;</p><p dir="RTL"><u>التوقف عن تناول فاموتيدين</u></p><p dir="RTL">إن عانيتَ قرحاتٍ بالمعدة أو الأمعاء مدةً طويلة، فلا يصح أن تنقطع عن تناول فاموتيدين عند الشعور بتحسن حتى تستشير الطبيب.</p><p>&nbsp;</p><p dir="RTL">إن كانت لك أسئلة أخرى عن استعمال هذا الدواء، فاسأل الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء آثارًا جانبية كحال جميع الأدوية، ولكنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>انقطع عن تناول فاموتيدين واتصل بالطبيب أو اذهب إلى قسم الطوارئ بأقرب مستشفًى فورًا إن وجدت أيًّا من الآثار التالية:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تصيب شخصًا من كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية الخطرة، لا سيما الطفح الجلدي والحكة والشرى، وضيق النَّفس والأزيز وصعوبة التنفس، وتورّم الوجه أو اليدين أو القدمين أو الفم أو الحلق أو العينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو ابيضاض العينين، أو لون البول الداكن، أو لون البراز الشاحب، أو فقد الشهية أو ألم البطن الدائمان، كل ذلك قد يكون علامات على عللٍ خطرة بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح شديد ببثور مع نزف في الشفتين والعينين والفم والأنف والأعضاء التناسلية، أو ردود فعل جلدية شديدة تبدأ باحمرار وألم في بعض المناطق، ثم تكون بثورًا كبيرة وتنتهي بنزف الطبقات السطحية من الجلد. قد تكون مصابًا بمتلازمة إستيفنز-جُنسون أي ما يعرَف بتقشُّر الأنسجة المُتموّتة البَشرَوِية التسممي (TEN)، وهو خطر على الحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بحرقة في الصدر، وضيق النَّفس، وسعال مستمر، وقد تكون هذه علامات على أنّ بك التهابًا رئويًّا شديدًا. قد تشعر بتعب أيضًا مع ازرقاق الشفتين والأنامل (الزُّراق) أو فقدان الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات أو التشنجات التي قد تفقدك الوعي، أو الصراخ، أو الانتفاض، أو الشعور بأَوْرَة تحذيرٍ سابقة (اضطراب إدراكي) قد يليه تشوش لذهنك أو تعب أو صداع شديد. إن كانت بك علل بالكُلى فأنت أكثر عرضة لمخاطر النوبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في النشاط الكهربي للقلب تُرى في مخطط كهربية الدماغ EEG. قد تشعر بخفة الرأس. مَن تناول مِن المرضى هذا الدواء بالحقن، طرأت له تغيرات في نظم القلب أو اضطربت ضربات قلبه.</p><p>&nbsp;</p><p dir="RTL"><strong>انقطع عن تناول فاموتيدين واتصل بالطبيب في أقرب وقت إن وجدت أيًّا من الآثار التالية:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تصيب شخصًا من كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الإصابة بحالات عدوى، فربما تصاب بحمّى، أو قشعريرة شديدة، أو التهاب الحلق، أو قرحات بالفم (وقد تكون هذه علامات على قلة خلايا الدم البيضاء في جسدك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة خلايا الدم الأخرى، وينجم عنه إرهاق، أو ضيق النَّفس، أو برودة اليدين والقدمين وشحوب الجلد (من قلة خلايا الدم الحمراء)، أو كدمات غير عادية أو نزف أكثر من المعتاد، أو صعوبة التئام الجروح (من قلة الصفائح الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب، أو تشوش الذهن، أو تَوَهان، أو توتر أو هياج، أو رؤية أشياء غير واقعية أو سماعها أو الشعور بها، وهي الهلاوس</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب شخصًا من كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بتعب غير معتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خروج الريح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة بالجلد أو طفح</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب شخصًا من كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد في الدم كما يُرى في فحص الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثدّي الرجال، ومع ذلك ليس مؤكدًا أن هذا الأثر ناجم عن فاموتيدين.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تصيب شخصًا من كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة بلوغ النشوة أو الإبقاء عليها، أو ضعف شهوة الجماع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل في أصابع اليدين والقدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نُعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في إنزيمات الكبد في الدم كما يُرى في فحص الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل وتقلص العضلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المبيَّن على الملصق، ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p><strong>&nbsp;</strong></p><p dir="RTL">يُحفَظ مسحوق فاموتيدين الجاف والمعلق المحضَّر في درجة حرارة 25 مئوية (77 فهرنهايت)، ومدى الحرارة المسموح بها من 15 إلى 30 مئوية (من 59 إلى 86 فهرنهايت).</p><p dir="RTL">يُحفظ من التجميد. يُتخلَّص من المعلق المحضَّر إن مرَّ عليه 30 يومًا من غير استعمال.</p><p dir="RTL">يصرَف الدواء في عبوة مقاومة للضوء ومحكمة الغلق (وفق دستور الأدوية الأمريكي).</p><p>&nbsp;</p><p dir="RTL">وقبل صرفه يحضَّر فاموتيدين لتكوين معلق فموي.</p><p>&nbsp;</p><p dir="RTL">لا يصح التخلص من الأدوية في مياه الصرف الصحي أو مع مخلفات المنزل. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستعملها؛ فهذه التدابير تساعد على الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات فاموتيدين</strong></p><p dir="RTL">يحتوي فاموتيدين المعلق الفموي على 40 ملغ من فاموتيدين لكل 5 مل.</p><p>&nbsp;</p><p dir="RTL"><strong>تشمل المكونات الأخرى ما يلي:</strong></p><p dir="RTL">سكر الحلوى</p><p dir="RTL">سليولوز دقيق التبلور أو صوديوم كربُكسي مِثيل السليولوز</p><p dir="RTL">صمغ الزَّنثان</p><p dir="RTL">بنزوات الصوديوم</p><p dir="RTL">صوديوم مِثيل البارابين</p><p dir="RTL">حمض ستريك لامائي</p><p dir="RTL">ماء منقًّى</p><p dir="RTL">نكهة النعناع</p><p dir="RTL">نكهة الكرز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل فاموتيدين ومحتويات العبوة</strong></p><p dir="RTL">الوصف: مسحوق أبيض أو أبيض مُصفرٌّ. إذا حضّرتَ معلق فاموتيدين وفق التوجيهات، فليكُن زَلِقًا متحركًا أبيضَ مصفرًّا متجانسًا بنكهة الكرز والنعناع، محتويًا على 40 ملغ من فاموتيدين لكل 5 مل.</p><p>&nbsp;</p><p dir="RTL">حجم العبوة: قارورة مثبَّت بغطائها نشرة الدواء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">نافينتا إل إل سي</p><p dir="RTL">إيوينغ، نيوجيرسي 08618، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أبوثيكون الخاصة المحدودة للأدوية</p><p dir="RTL">العنوان: قطع الأرض ذوات الأرقام 1134، و1135، و1136، و1137،</p><p dir="RTL">و1138 &ndash; (أ) و(ب)، و1143 &ndash; (ب)، و1144 &ndash; (أ) و(ب)، طريق بَدرا جَمبوسار،</p><p dir="RTL">دَبهاسا، بَدرا، مقاطعة فادودارا، ولاية غوجارات &ndash; 391440، الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجِعَت هذه النشرة آخر مرة في سبتمبر/أيلول 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famotidine for Oral Suspension USP, 40 mg/5 mL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famotidine For Oral Suspension USP, 40 mg/5 mL is a white to off white powder containing 400 mg of Famotidine per 50 mL provided in HDPE bottle for constitution. When constituted as directed, Famotidine for Oral Suspension is a smooth, mobile, off-white homogenous suspension with a flavor containing 40mg of Famotidine per 5 mL.

Excipients with known effect
This medicine contains 5.00 mg of Sodium Benzoate in each dosage unit.
This medicinal product contains up to 0.798 mg sodium per unit dose.
For the full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Famotidine indicated in adults for the treatment of:</p><p>&bull; active duodenal ulcer (DU).</p><p>&bull; active gastric ulcer (GU).</p><p>&bull; symptomatic nonerosive gastroesophageal reflux disease (GERD).</p><p>&bull; erosive esophagitis due to GERD, diagnosed by biopsy.</p><p>&bull; treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).</p><p>&bull; reduction of the risk of duodenal ulcer recurrence.</p><p>&nbsp;</p><p>Famotidine is indicated in pediatric patients 1 year of age and older for the treatment of:</p><p>&bull; peptic ulcer disease.</p><p>&bull; GERD with or without esophagitis and ulcerations.</p><p>&nbsp;</p><p>Famotidine is indicated in pediatric patients from birth to less than 1 year of age for the treatment of:</p><p>&bull; GERD</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Recommended Dosage in Adults</u></p><p>The recommended dosage and duration of famotidine in adults with normal renal function is shown in Table 1.</p><p>&nbsp;</p><p>Table 1: Recommended Dosage and Duration of Famotidine for Oral Suspension<sup>a</sup> in Adults with</p><p>Normal Renal Function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Recommended duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Active DU</p></td><td style="vertical-align:top"><p>40 mg once daily; or 20 mg twice daily<sup>b</sup></p></td><td style="vertical-align:top"><p>Up to 8 weeks<sup>c,d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Active GU</p></td><td style="vertical-align:top"><p>40 mg once daily</p></td><td style="vertical-align:top"><p>Up to 8 weeks<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic nonerosive GERD</p></td><td style="vertical-align:top"><p>20 mg twice daily</p></td><td style="vertical-align:top"><p>Up to 6 weeks<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Erosive esophagitis due to GERD, diagnosed by endoscopy</p></td><td style="vertical-align:top"><p>20 mg twice daily; or 40 mg twice daily<sup>b</sup></p></td><td style="vertical-align:top"><p>Up to 12 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Pathological hypersecretory conditions</p></td><td style="vertical-align:top"><p>Starting dosage: 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours</p></td><td style="vertical-align:top"><p>As clinically indicated</p></td></tr><tr><td style="vertical-align:top"><p>Reduction of the risk of DU recurrence</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>1 year<sup>c,d</sup> or as clinically indicated</p></td></tr></tbody></table><p>a&nbsp;&nbsp; After preparation, the concentration of famotidine is 8 mg/mL</p><p>b&nbsp;&nbsp; Both dosages demonstrated effectiveness in clinical trials</p><p>c&nbsp;&nbsp; In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 &nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; weeks, consider an additional 2 to 4 weeks of treatment</p><p>d&nbsp;&nbsp; Longer treatment durations have not been studied in clinical trials</p><p>&nbsp;</p><p><u>Recommended Dosage in Paediatric Patients</u></p><p>The recommended dosage and duration of famotidine in paediatric patients with normal renal function is shown in Table 2.</p><p>&nbsp;</p><p>Table 2: Recommended Dosage and Duration of Famotidine for Oral Suspension<sup>a</sup> in Paediatric Patients with Normal Renal Function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Age</strong></p><p><strong>Range</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dosage<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Peptic Ulcer</strong></p><p><strong>Disease</strong></p></td><td style="vertical-align:top"><p>1 year to less than</p><p>17 years</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg once daily; or 0.25 mg/kg twice daily.</p><p>&nbsp;</p><p>May increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily</p><p>&nbsp;</p><p>Maximum of 40 mg per day</p></td><td style="vertical-align:top"><p>8 weeks<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>GERD</strong></p></td><td style="vertical-align:top"><p>Birth to less than</p><p>3 months</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg once daily.</p><p>May increase to 1 mg/kg once daily<sup>b</sup></p></td><td rowspan="2" style="vertical-align:top"><p>Up to 8 weeks<sup>b,c,d</sup></p></td></tr><tr><td style="vertical-align:top"><p>3 months to less than</p><p>1 year</p></td><td style="vertical-align:top"><p>Starting dosage 0.5 mg/kg twice daily.</p><p>May increase to 1 mg/kg twice daily<sup>c</sup></p><p>&nbsp;</p><p>Maximum of 40 mg per day</p></td></tr><tr><td style="vertical-align:top"><p><strong>GERD with or</strong></p><p><strong>without</strong></p><p><strong>esophagitis and</strong></p><p><strong>ulcerations</strong></p></td><td style="vertical-align:top"><p>1 year to less than</p><p>17 years</p></td><td style="vertical-align:top"><p>0.5 mg/kg twice daily</p><p>Maximum of 40 mg twice daily</p></td><td style="vertical-align:top"><p>6 to 12 weeks<sup>b</sup></p></td></tr></tbody></table><p>a&nbsp;&nbsp; After preparation, the concentration of famotidine is 8 mg/mL</p><p>b&nbsp;&nbsp; Treatment duration based on adult recommendations (see Table 1). Individualize the dose and</p><p>&nbsp;&nbsp;&nbsp;&nbsp; duration based upon clinical response and/or pH determinations (gastric or esophageal) and &nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; endoscopy.</p><p>c&nbsp;&nbsp; Use conservative measures (e.g., thickened feedings) concurrently</p><p>d&nbsp;&nbsp; After 4 weeks of treatment re-evaluate the patient. Consider an additional 4 weeks of treatment if</p><p>&nbsp;&nbsp;&nbsp;&nbsp; treatment benefit outweighs potential risks.</p><p>&nbsp;</p><p><u>Recommended Dosage in Adults with Renal Impairment</u></p><p>Recommended dosage adjustments for adults with moderate to severe renal impairment (creatinine</p><p>clearance less than 60 mL/min) by indication are shown in Table 3. Use the lowest effective dosage.</p><p>A safe and effective dosage has not been established in paediatric patients with renal impairment.</p><p>&nbsp;</p><p>Table 3: Recommended Maximum Dosage of Famotidine for Oral Suspension in Adults with</p><p>Moderate and Severe Renal Impairment</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Indication</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp; Recommended Maximum dosages</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine clearance 30 to 60 mL/minute</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance less than 30 ML/minute</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Active DU</strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Active GU</strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td style="vertical-align:top"><p><strong>Symptomatic nonerosive GERD</strong></p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Erosive esophagitis due to GERD, diagnosed by endoscopy<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>20 mg once daily; or 40 mg every other day<sup>b</sup></p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>40 mg once daily<sup>b</sup></p></td><td style="vertical-align:top"><p>20 mg once daily<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pathological hypersecretory conditions</strong></p></td><td colspan="2" style="vertical-align:top"><p>Avoid use<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Reduction of the risk of DU recurrence</strong></p></td><td style="vertical-align:top"><p>10 mg once daily; or 20 mg every other day</p></td><td style="vertical-align:top"><p>10 mg every other day</p></td></tr></tbody></table><p>a Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials</p><p>b The dosage required to treat pathological hypersecretory conditions may exceed the maximum dosage evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine for pathological hypersecretory conditions is unknown.</p><p>&nbsp;</p><p><strong><u>Special populations</u></strong></p><p><strong><u>Paediatric Use </u></strong></p><p>Peptic Ulcer Disease and GERD With or Without Esophagitis and Ulcerations</p><p><em>Paediatric Patients One Year to Less than 17 Years of Age</em></p><p>The safety and effectiveness of famotidine for oral suspension have been established in paediatric patients 1 year to less than 17 years of age for the treatment of peptic ulcer disease and GERD with or without esophagitis and ulcerations. Use of famotidine in this age group is supported by evidence from adequate and well-controlled studies of famotidine in adults with additional pharmacokinetic and pharmacodynamic data in paediatric patients 1 year to less than 17 years of age <em>[see </em><em>Posology and method of administration</em><em> (4.2), Pharmacological properties (5.1, 5.2)]. </em>The safety and effectiveness of famotidine for oral suspension for the treatment of peptic ulcer disease in paediatric patients less than one year of age have not been established.</p><p>&nbsp;</p><p>GERD</p><p><em>Paediatric Patients Less Than One Year of Age</em></p><p>The safety and effectiveness of famotidine for oral suspension have been established in paediatric patients from birth to less than 1 year of age for the treatment of GERD. The use of famotidine this is age group is supported by evidence from adequate and well-controlled studies of famotidine in adults and with supportive data in paediatric patients from birth to less than 1 year of age <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2), Pharmacological properties (5.1, 5.2)].</em></p><p>&nbsp;</p><p>Other Conditions</p><p>The safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established in paediatric patients.</p><p>A safe and effective dosage has not been established in paediatric patients with renal impairment.</p><p>&nbsp;</p><p><strong><u>Geriatric Use</u></strong></p><p>Of the 1442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older. In</p><p>these studies, no overall differences in safety or effectiveness were observed between elderly and</p><p>younger patients. In post marketing experience, CNS adverse reactions have been reported in elderly</p><p>patients with and without renal impairment receiving famotidine <em>[see Warnings and Precautions (4.4)].</em></p><p>&nbsp;</p><p>Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to</p><p>famotidine for oral suspension may be greater in elderly patients, particularly those with impaired renal</p><p>function <em>[see Use in Specific Populations (renal impairment)].</em></p><p>&nbsp;</p><p>In general, use the lowest effective dose of famotidine for oral suspension for an elderly patient and</p><p>monitor renal function <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2)].</em></p><p>&nbsp;</p><p><strong><u>Renal Impairment </u></strong></p><p>CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate and severe renal impairment <em>[see Warnings and Precautions (4.4)]. </em>The clearance of famotidine is reduced in adults with moderate and severe renal impairment compared to adults with normal renal function <em>[see&nbsp; Pharmacological properties (5.2)]. </em>No dosage adjustment is needed in adults with mild renal impairment (creatinine clearance greater than or equal to 60 mL/minute). Dosage reduction is recommended in adults with moderate or severe renal impairment (creatinine clearance less than 60 mL/minute) <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2)]. </em>Data are not available to establish a safe and effective dosage in paediatric patients with renal impairment.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>Preparation of Constituted Suspension </u></p><p>Prior to dispensing, constitute famotidine by slowly adding 46 ml of Purified water to the bottle. Shake vigorously for the 5 to 10 seconds immediately after adding the water. The constituted suspension contains 40 mg of famotidine per 5 ml, and should be a<em> </em>smooth, mobile, off-white, and homogeneous suspension.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the bottle of constituted suspension vigorously for 5 to 10 seconds prior to each use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take famotidine once daily before bedtime or twice daily in the morning and before bedtime.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Famotidine may be taken with or without food</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Famotidine may be given with antacids (famotidine should be administered 1-2 hours before taking an antacid).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the constituted suspension at 25&deg;C (77&deg;F). Protect from freezing. Discard unused constituted suspension after 30 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famotidine for oral suspension is contraindicated in patients with a history of serious hypersensitivity
reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H2) receptor antagonists.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Central Nervous System Adverse Reactions</strong></p><p>Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function dosage adjustments are recommended in patients with renal impairment.</p><p>&nbsp;</p><p><strong>Concurrent Gastric Malignancy</strong></p><p>In adults, symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with famotidine for oral suspension.</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>Since famotidine is excreted primarily by the kidney, caution should be observed in patients with</p><p>impaired renal function. A reduction in daily dosage should be considered if creatinine clearance falls</p><p>below 30 ml/min <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2)].</em></p><p><em>&nbsp;</em></p><p>In case of long-term treatment with high dosage, monitoring of blood count and liver function is</p><p>recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drugs Dependent on Gastric pH for Absorption</strong></p><p>Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity,</p><p>leading to loss of efficacy of the concomitant drug.</p><p>Concomitant administration of famotidine for oral suspension with dasatinib, delavirdine mesylate,</p><p>cefditoren, and fosamprenavir is not recommended.</p><p>See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/ sofosbuvir, nilotinib, and rilpivirine.</p><p>&nbsp;</p><p>The administration of probenecid can delay the elimination of famotidine. Concomitant use of</p><p>probenecid and famotidine should be avoided.</p><p>&nbsp;</p><p>Antacids may decrease the absorption of famotidine and lead to lower plasma concentrations of</p><p>famotidine. Famotidine should therefore be taken 1 - 2 hours before the application of an antacid.</p><p>&nbsp;</p><p>The concomitant use of sucralfate should be avoided within two hours of the famotidine dose.</p><p>&nbsp;</p><p>The concomitant use of Calcium carbonate and famotidine should be avoided.</p><p><strong>&nbsp;</strong></p><p><strong>Tizanidine (CYP1A2 Substrate)</strong></p><p>Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to</p><p>substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use</p><p>with famotidine for oral suspension. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><u>&nbsp;</u></p><p>Pregnancy Category C</p><p>&nbsp;</p><p><u>Risk Summary</u></p><p>Available data with H<sub>2</sub> -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.</p><p>In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis <em>(see Data).</em></p><p>The estimated background risk for major birth defects and miscarriage for the indicated population is</p><p>unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the</p><p>U.S. general population, the background risk of major birth defects and miscarriage in clinically</p><p>recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p>&nbsp;</p><p>Data</p><p><em>Animal Data</em></p><p>Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg</p><p>/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg per day, based on body surface area) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p><p>&nbsp;</p><p><u>Lactation</u></p><p><u>Risk Summary</u></p><p>There are limited data available on the presence of famotidine in human breast milk. There were no</p><p>effects on the breastfed infant. There are no data on famotidine effects on milk production. Famotidine is present in the milk of lactating rats <em>(see Data).</em></p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&#39;s</p><p>clinical need for famotidine and any potential adverse effects on the breastfed child from famotidine for</p><p>oral suspension or from the underlying maternal condition.</p><p>&nbsp;</p><p>Data</p><p><em>Animal Data</em></p><p>Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of famotidine at least 600 times the usual human dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in</p><p>the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The safety of famotidine for oral suspension has been established based on adequate and well controlled</p><p>studies of another oral famotidine product. The following is a summary of the adverse reactions reported in those studies.</p><p>Oral famotidine was studied in 7 US and international placebo- and active-controlled trials in</p><p>approximately 2500 patients. A total of 1442 patients were treated with famotidine, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily. The population was 17 to 91 years old, fairly well distributed between sex and race; however, the predominant race was Caucasian.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp; <u>Tabulated summary of adverse reactions</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Organ class system</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Side effects</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Leukopenia</p><p>Agranulocytosis</p><p>Pancytopenia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hallucinations</p><p>Disorientation</p><p>Confusion</p><p>Anxiety</p><p>Agitation</p><p>Depression</p><p>Impotence</p><p>Reduced libido</p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common (&gt; 1/100, &lt; 1/10):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia</p><p>Somnolence</p><p>Insomnia</p><p>Epileptic seizures</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Common (&gt; 1/100, &lt; 1/10):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation</p><p>Diarrhoea</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Uncommon (&gt;1/1000, &lt; 1/100):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Abdominal discomfort or distension</p><p>Flatulence</p><p>Fatigue</p><p>Dry mouth</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Rare (&gt;1/10,000, &lt; 1/1000):</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in liver enzyme abnormalities (transaminases, gamma GT, alkaline phosphatase, bilirubin)</p><p>Intrahepatic cholestasis (visible sign: jaundice)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><em>Uncommon (&gt;1/1000, &lt; 1/100):</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Loss of appetite</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><em>Uncommon (&gt;1/1000, &lt; 1/100):</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare (&gt;1/10,000, &lt; 1/1000):</em></p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000)</em></p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><em>Rare (&gt;1/10,000, &lt; 1/1000):</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (angioneurotic oedema, anaphylaxis, bronchospasm)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000):</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Chest tightness</p><p>Severe skin reactions (toxic epidermal necrolysis)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Muscoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p><em>Rare (&gt;1/10,000, &lt; 1/1000):</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Arthralgia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><em>Very rare (&lt; 1/10,000):</em></p></td><td style="vertical-align:top"><p>Muscle cramps</p></td></tr></tbody></table><p>&nbsp;</p><p>c. <u>Paediatric Population</u></p><p>Peptic Ulcer Disease and GERD With or Without Esophagitis and Ulcerations</p><p><em>Paediatric Patients One Year to Less than 17 Years of Age</em></p><p>The safety and effectiveness of famotidine for oral suspension have been established in paediatric patients 1 year to less than 17 years of age for the treatment of peptic ulcer disease and GERD with or without esophagitis and ulcerations. Use of famotidine in this age group is supported by evidence from adequate and well-controlled studies of famotidine in adults with additional pharmacokinetic and pharmacodynamic data in paediatric patients 1 year to less than 17 years of age <em>[</em><em>Posology and method of administration</em><em> (4.2), Pharmacological properties (5.1, 5.2)]. </em>The safety and effectiveness of famotidine for oral suspension for the treatment of peptic ulcer disease in paediatric patients less than one year of age have not been established.</p><p>&nbsp;</p><p>GERD</p><p><em>Paediatric Patients Less Than One Year of Age</em></p><p>The safety and effectiveness of famotidine for oral suspension have been established in paediatric patients from birth to less than 1 year of age for the treatment of GERD. The use of famotidine this is age group is supported by evidence from adequate and well-controlled studies of famotidine in adults and with supportive data in paediatric patients from birth to less than 1 year of age <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2), Pharmacological properties (5.1, 5.2)].</em></p><p>&nbsp;</p><p>Other Conditions</p><p>The safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of duodenal ulcer recurrence have not been established in paediatric patients.</p><p>A safe and effective dosage has not been established in paediatric patients with renal impairment.</p><p>&nbsp;</p><p>d<strong>. </strong><u>Geriatric Use</u></p><p>Of the 1442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older. In</p><p>these studies, no overall differences in safety or effectiveness were observed between elderly and</p><p>younger patients. In post marketing experience, CNS adverse reactions have been reported in elderly</p><p>patients with and without renal impairment receiving famotidine <em>[see Warnings and Precautions (4.4)].</em></p><p>&nbsp;</p><p>Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to</p><p>famotidine for oral suspension may be greater in elderly patients, particularly those with impaired renal</p><p>function <em>[see Use in Specific Populations (renal impairment)].</em></p><p>&nbsp;</p><p>In general, use the lowest effective dose of famotidine for oral suspension for an elderly patient and</p><p>monitor renal function <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2)].</em></p><p><em>&nbsp;</em></p><p>e. <u>Renal Impairment</u></p><p>CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate</p><p>and severe renal impairment <em>[see Warnings and Precautions (4.4)]. </em>The clearance of famotidine</p><p>is reduced in adults with moderate and severe renal impairment compared to adults with normal</p><p>renal function <em>[see Pharmacological properties (5.2)]. </em>No dosage adjustment is needed in adults</p><p>with mild renal impairment (creatinine clearance greater than or equal to 60 mL/minute). Dosage</p><p>reduction is recommended in adults with moderate or severe renal impairment (creatinine clearance less than 60 mL/minute) <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2)]. </em>Data are not available</p><p>to establish a safe and effective dosage in paediatric patients with renal impairment.</p><p><strong>To report any side effect(s):<br />Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&bull; The National Pharmacovigilance Centre (NPC)<br />&bull; &bull;SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>Other GCC states /other countries</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The types of adverse reactions in overdosage of famotidine are similar to the adverse reactions</p><p>encountered with use of recommended dosages<em>.</em></p><p>In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material</p><p>should be removed from the gastrointestinal tract, the patient should be monitored, and supportive</p><p>therapy should be employed.</p><p>Due to low binding to plasma proteins, famotidine is eliminated by haemodialysis. There is limited</p><p>experience on the usefulness of haemodialysis as a treatment for famotidine overdosage.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Histamine H2 receptor antagonist, ATC code: A02B A03</p><p>&nbsp;</p><p><u>Pharmacodynamics</u></p><p><em>Adults</em></p><p>Famotidine inhibited both basal and nocturnal gastric secretion, as well as secretion stimulated by food</p><p>and pentagastrin. After oral administration of famotidine, the onset of the antisecretory effect occurred</p><p>within one hour; the maximum effect was dose-dependent, occurring within one to three hours. Duration</p><p>of inhibition of secretion by doses of 20 mg and 40 mg was 10 to 12 hours.</p><p>&nbsp;</p><p>Single evening oral doses of 20 mg and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid</p><p>secretion in all subjects. The mean suppression was 76% and 84%, respectively, 3 to 5 hours after</p><p>administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects</p><p>who received the 20 mg dose, however, the antisecretory effect was dissipated within 6 to 8 hours.</p><p>There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by</p><p>evening doses of 20 mg and 40 mg of famotidine to mean values of 5.0 and 6.4, respectively. When</p><p>famotidine was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 mg or</p><p>40 mg of famotidine was raised to about 5.</p><p>&nbsp;</p><p>Famotidine had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and</p><p>exocrine pancreatic function were not affected by famotidine.</p><p>&nbsp;</p><p>In clinical pharmacology studies, systemic effects of famotidine in the CNS, cardiovascular, respiratory</p><p>or endocrine systems were not noted. Also, no anti-androgenic effects were noted.</p><p>Serum hormone levels, including prolactin, cortisol, thyroxine (T<sub>4</sub>), and testosterone, were not altered</p><p>after treatment with famotidine.</p><p>&nbsp;</p><p><em>Paediatric Patients</em></p><p>Pharmacodynamics of famotidine, assessed by gastric pH, were evaluated in 5 paediatric patients 2</p><p>years to 13 years of age using the sigmoid E<sub>max </sub>model. These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in adults (see Table 4).</p><p>&nbsp;</p><p><strong>Table 4: Serum Concentrations of Famotidine Associated with Gastric Acid Reduction in</strong></p><p><strong>Famotidine- Treated Paediatric and Adult Patients<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>EC<sub>50</sub> (ng/mL)<sup>a</sup></u></p></td></tr><tr><td style="vertical-align:top"><p>Paediatric Patients</p></td><td style="vertical-align:top"><p>26 &plusmn; 13</p></td></tr><tr><td style="vertical-align:top"><p>Adults</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Healthy adult subjects</p></td><td style="vertical-align:top"><p>26.5 &plusmn; 10.3</p></td></tr><tr><td style="vertical-align:top"><p>Adult patients with upper GI bleeding</p></td><td style="vertical-align:top"><p>18.7 &plusmn; 10.8</p></td></tr></tbody></table><p>a<sup> </sup>Using the Sigmoid E<sub>max</sub> model, serum concentrations of famotidine associated with 50% maximum</p><p>gastric acid reduction are presented as means &plusmn; SD.</p><p>In a study examining the effect of famotidine on gastric pH and duration of acid suppression in paediatric patients, four paediatric patients ages 11 to 15 years of age using the oral formulation at a dose of 0.5 mg/kg, maintained a gastric pH above 5 for 13.5 &plusmn; 1.8 hours.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Famotidine is a competitive inhibitor of histamine-2 (H<sub>2</sub>) receptors. The primary clinically important</p><p>pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and</p><p>volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are</p><p>proportional to volume output.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral administration</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability</p><p>may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no</p><p>clinical consequence.</p><p>&nbsp;</p><p>Peak famotidine plasma levels occur in 1 to 3 hours. Plasma levels after multiple dosages are similar to</p><p>those after single doses.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Fifteen to 20% of famotidine in plasma is protein bound.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><em>Metabolism</em></p><p>Famotidine undergoes minimal first-pass metabolism. Twenty-five to 30% of an oral dose was</p><p>recovered in the urine as unchanged compound. The only metabolite identified in humans is the</p><p>S-oxide.</p><p><em>Excretion</em></p><p>Famotidine has an elimination half-life of 2.5-3.5 hours. Famotidine is eliminated by renal (65 to</p><p>70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/minute, indicating</p><p>some tubular excretion.</p><p>&nbsp;</p><p><u>Specific Populations</u></p><p><em>Paediatric Patients</em></p><p><em>Infants from birth to 12 Months</em></p><p>After a single oral dose administration of 0.5 mg/kg orally in patients from birth to 12 months, the</p><p>bioavailability is approximately 42%.</p><p>&nbsp;</p><p>The AUC increased 1.4-fold after single oral dose of 1 mg/kg compared to 0.5 mg/kg and 2.7-fold</p><p>after multiple oral doses of 1 mg/kg compared to 0.5 mg/kg.</p><p>&nbsp;</p><p>Plasma clearance is reduced and elimination half-life is prolonged in paediatric patients from birth</p><p>to 3 months of age compared to older paediatric patients. Following intravenous administration of</p><p>0.5 mg/kg, CL<sub>Total </sub>was 0.13 &plusmn;0.06 L/hr/kg, 0.21 &plusmn; 0.06 L/hr/kg, and 0.49 &plusmn; 0.17 L/hr/kg in paediatric patients &lt;1 month of age, &lt;3 months of age, and &gt;3 to 12 months of age, respectively.</p><p>Elimination half-life was 10.5 hours, 8.1 hours, and 4.5 hours in paediatric patients &lt;1 month of</p><p>age, &lt;3 months of age, and &gt;3 to 12 months of age, respectively.</p><p><em>&nbsp;</em></p><p><em>Patients 11 Years to 15 Years</em></p><p>The mean bioavailability in 8 paediatric patients was 50% compared to adult values of 42% to 49%.</p><p>Pharmacokinetic parameters in paediatrics 11 years to 15 years is compared to infants from birth to 12</p><p>months in Table 5.</p><p>&nbsp;</p><p><strong>Table 5: Mean Pharmacokinetic Parameters Following a Single Oral Dose of 0.5 mg/kg in Infants and Paediatric Patients</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infants from Birth to 12 Months (N=5)</p></td><td style="vertical-align:top"><p>Paediatric Patients 11 Years to 15 Years (N=8)</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-&infin;</sub> (ng*hr/mL)<sup>a</sup></p></td><td style="vertical-align:top"><p>645 &plusmn; 249</p></td><td style="vertical-align:top"><p>580 &plusmn; 60</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/mL)</p></td><td style="vertical-align:top"><p>79.2</p></td><td style="vertical-align:top"><p>97.3</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max</sub> (hr)<sup>b</sup></p></td><td style="vertical-align:top"><p>2.0 (1.0, 4.1)<sup>c</sup></p></td><td style="vertical-align:top"><p>2.3 (2.1, 2.9)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>T<sub>1/2 </sub>(hr)</p></td><td style="vertical-align:top"><p>5.82</p></td><td style="vertical-align:top"><p>2.13</p></td></tr></tbody></table><p>a arithmetic mean &plusmn; S.D.</p><p>b median</p><p>c observed minimum and maximum values</p><p>d reported minimum and maximum values</p><p>&nbsp;</p><p><em>Patients with Renal Impairment</em></p><p>In adult patients with severe renal impairment (creatinine clearance less than 30 mL/minute), the systemic exposure (AUC) of famotidine increased at least 5-fold. In adult patients with moderate renal impairment (creatinine clearance between 30 to 60 mL/minute), the AUC of famotidine increased at least 2-fold <em>[see </em><em>Posology and method of administration</em><em> </em><em>(4.2), Use in Specific Populations (renal impairment)].</em></p><p><em>&nbsp;</em></p><p>Drug Interaction Studies</p><p><em>Human Organic Anion Transporter (OAT) 1 and 3: </em>In vitro studies indicate that famotidine is a substrate for OAT1 and OAT3. Following coadministration of probenecid (1500 mg), an inhibitor of OAT1 and OAT3, with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC<sub>0 10h</sub> of famotidine increased from 424 to 768 ng∙hr/mL and the maximum serum concentration (C<sub>max</sub>) increased from 73 to 113 ng/mL. Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased. The clinical relevance of this interaction is unknown.</p><p>&nbsp;</p><p><em>Multidrug and Toxin Extrusion Protein 1 (MATE-1): </em>An in vitro study showed that famotidine is an</p><p>inhibitor of MATE-1.</p><p>However, no clinically significant interaction with metformin, a substrate for MATE-1, was observed.</p><p><em>CYP1A2: </em>Famotidine is a weak CYP1A2 inhibitor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p>Carcinogenic potential of famotidine was assessed in a 106-week oral carcinogenicity study in rats and a</p><p>92-week oral carcinogenicity study in mice. In the 106-week study in rats and the 92-week study in mice at oral doses of up to 2000 mg/kg/day (approximately 243 and 122 times, respectively, based on body</p><p>surface area, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis),</p><p>there was no evidence of carcinogenic potential for famotidine.</p><p>&nbsp;</p><p>Famotidine was negative in the microbial mutagen test (Ames test) using <em>Salmonella typhimurium </em>an<em>d</em></p><p><em>Escherichia coli </em>with or without rat liver enzyme activation at concentrations up to 10,000 mcg/plate. In <em>in vivo </em>studies in mice, with a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was observed.</p><p>&nbsp;</p><p>In studies with rats given oral doses of up to 2000 mg/kg/day (approximately 243 times, based on body</p><p>surface area, the recommended human dose of 80 mg per day) fertility and reproductive performance were not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Confectioners sugar</p><p>Microcrystalline Cellulose/Carboxy methyl Cellulose sodium</p><p>Xanthan gum</p><p>Sodium benzoate</p><p>Methyl Paraben sodium</p><p>Citric acid anhydrous</p><p>Purified water</p><p>Mint flavour</p><p>Cherry flavour</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store famotidine dry powder and constituted suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F)</p><p>Protect from freezing. Discard unused constituted suspension after 30 days.</p><p>&nbsp;</p><p>Dispense in a USP tight, light-resistant container.</p><p>&nbsp;</p><p>Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Famotidine For Oral Suspension USP, 40 mg/5 mL is a white to off white powder containing 400 mg of Famotidine per 50 mL provided in HDPE bottle for constitution. When constituted as directed, Famotidine for Oral Suspension is a smooth, mobile, off-white homogenous suspension with a flavour containing 40mg of Famotidine per 5 mL.</p><p>&nbsp;</p><p>Pack size: Bottle with the leaflet fixed to the bottle cap..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Navinta LLC,
1499 Lower Ferry Road,
Ewing, NJ-08618-1414, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>